Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency

作者：Grossman Jennifer; Cuellar Rodriguez Jennifer; Gea Banacloche Juan; Zerbe Christa; Calvo Katherine; Hughes Thomas; Hakim Fran; Cole Kristen; Parta Mark; Freeman Alexandra; Holland Steven M; Hickstein Dennis D^*

来源：Biology of Blood and Marrow Transplantation, 2014, 20(12): 1940-1948.

DOI：10.1016/j.bbmt.2014.08.004

• GATA2
• Hematopoietic stem cell transplantation
• Myelodysplastic syndrome
• Familial acute myelogenous leukemia

We treated 14 patients with GATA2 deficiency using a nonmyeloablative allogeneic hematopoietic stem cell transplantation regimen. Four patients received peripheral blood stem cells from matched related donors (MRD), 4 patients received peripheral blood stem cells from matched unrelated donors (URD), 4 patients received hematopoietic stem cells from umbilical cord blood donors (UCB), and 2 patients received bone marrow cells from haploidentical related donors. MRD and URD recipients received conditioning with 3 days of fludarabine and 200 cGy total body irradiation (TBI). Haploidentical related donor recipients and UCB recipients received cyclophosphamide and 2 additional days of fludarabine along with 200 cGY TBI. MRD, URD, and UCB recipients received tacrolimus and sirolimus for post-transplantation immunosuppression, whereas haploidentical recipients received high-dose cyclophosphamide followed by tacrolimus and mycophenolate mofetil. Eight patients are alive with reconstitution of the severely deficient monocyte, B cell, and natural killer cell populations and reversal of the clinical phenotype at a median follow-up of 3.5 years. Two patients (I URD recipient and 1 UCB recipient) rejected the donor graft and 1 MRD recipient relapsed with myelodysplastic syndrome after transplantation. We are currently using a high-dose conditioning regimen with busulfan and fludarabine in patients with GATA2 deficiency to achieve more consistent engraftment and eradication of the malignant myeloid clones. Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.

• 出版日期2014-12